top of page
Akamis Bio Header Image

News Archives

May 6, 2025

Akamis Bio Broadens Leadership Team with Key Executive Appointments

Apr 3, 2025

Akamis Bio Announces Enrollment of First Patient in Phase 1b FORTRESS Trial of NG-350A in Patients with Locally Advanced Rectal Cancer

Dec 17, 2024

Akamis Bio Announces $60 Million in Funding Linked to Series A Prime Financing and New Strategic Partnership

Oct 23, 2024

Akamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload

October 3, 2023

Akamis Bio Highlights Data Showing Potential of its Adenovirus Vector Technology in Combination with Radiation to Treat Advanced Rectal Cancer

July 6, 2023

Akamis Bio Strengthens Leadership Team with Key Executive Appointments

February 16, 2023

Akamis Bio, Parker Institute for Cancer Immunotherapy and Cancer Research Institute
Announce Expanded Partnership to Advance Novel Treatments for Pancreatic Cancer

January 5, 2023

Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics

August 11, 2022

PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer

bottom of page